跳至主要内容
临床试验/EUCTR2020-005984-29-NL
EUCTR2020-005984-29-NL进行中(未招募)1 期

[89Zr]Df-IAB22M2C anti-CD8 minibody PET/CT imaging to assess the in vivo distribution of CD8+ T-cells in COVID-19 patients

Radboud University Medical Center0 个研究点目标入组 20 人开始时间: 2021年1月12日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • All patients must meet all of the following criteria:
  • 1. microbiologically proven SARS-CoV-19 infection;
  • 2. More than or equal to 18 years of age;
  • 3. Ability to provide written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • A patient will be excluded from participation in the trial if one or more of the following criteria are met:
  • 1. Contra-indication for PET; pregnancy, breast-feeding, severe claustrophobia
  • 2. Contra-indication for administration of iodine-containing contrast agents
  • 3. Other serious illness, e.g. history of malignancies or auto-immune disorders
  • 4. Known pre-existing lymphopenia from an unrelated other medical condition
  • 5. Estimated creatinine clearance = 30mL/min according to the Cockcroft-Gault formula (or local institutional standard method) OR oligo-uric patients (<400mL/24hr)

研究者

相似试验